India IPO SEBI DRHP Activity Filings — March 10, 2026

NSE listing approval (letter NSE/LIST/246) for 25,10,36,900 shares of Re. 1 FV on Main Board effective Mar 12, 2026, completing IPO process

High materiality 10/10 rating with positive sentiment, no delays vs peers like Mahamaya, positioning for immediate trading liquidity

Stock symbol AEPL (EQ series) confirmed, BSE intimation per SEBI LODR, enabling dual-listing access for investors

44% IPO proceeds (₹27.47 Cr utilized of ₹61.96 Cr total) deployed safely, unutilized ₹34.49 Cr parked in compliant instruments amid delays

No change in original prospectus objects (Nov 14, 2025), board approval via circular resolution maintains capex integrity for Technical Manufacturing Plant

Funds remain in interest-bearing permitted instruments, preserving value vs cash drag, with Audit Committee oversight

Artemis achieves 100% listing milestone vs Mahamaya's partial proceeds use (44% QoQ since Nov 2025), relative outperformance in IPO execution

Rescheduling to Mar 31, 2028 accounts for procurement cycles and sequential projects, avoiding rushed deployments

CIN L51505MH2009PLC196683 with established profile, listing unlocks shareholder liquidity post-IPO

1/2 filings show full listing completion (Artemis), signaling sector maturation vs deployment lags

Continued Reg 32 disclosures ensure transparency on utilization, building investor trust

Effective listing Mar 12 enables price discovery, potential first-day pop typical for NSE Main Board IPOs

Only ₹27.47 Cr (44%) of ₹61.96 Cr IPO proceeds utilized as of Feb 28, 2026—4+ months post-Nov 2025 receipt—due to FY25-26 window limits

Sequential stages for new Technical Manufacturing Plant cited for rescheduling, potential timeline slippage to 2028

Unutilized ₹34.49 Cr (56%) represents deployment lag vs expected full use, neutral sentiment reflects mixed execution

Fresh NSE Main Board listing (25.1 Cr shares) Mar 12, 2026, no financial data disclosed, susceptible to debut volatility

Rescheduling requires ongoing Monitoring Agency reports and Audit Committee reviews per Reg 32, non-compliance risk

1/2 recent IPOs (Mahamaya) show partial proceeds use <50% within 4 months, outlier vs smooth listings like Artemis

Parked funds in instruments yield interest but delay growth vs peers with faster capex

No financial performance, ratios, or operational metrics disclosed, limiting pre-listing assessment

Trade AEPL from Mar 12, 2026 on NSE Main Board, capture listing premium with positive sentiment and 10/10 materiality

25.1 Cr shares at Re. 1 FV enable broad access, potential undervaluation at debut vs IPO price

Rescheduling to Mar 31, 2028 provides multi-year runway for plant capex without object changes, buy on dip if shares react negatively

₹34.49 Cr unutilized earning interest, low-risk hold for sequential project milestones

Outperforms Mahamaya in execution (full listing vs 44% utilization), alpha from IPO completers

Reg 32 monitoring enhances governance, invest ahead of utilization updates

Long Artemis listing vs monitor Mahamaya delays, sector rotation into completed IPOs

NSE approval + BSE intimation sets dual-listing, volume opportunity post-Mar 12

Plant expansion intact, utilization ramp post-FY26 could drive revenue growth

AEPL ticker ready, early positioning for post-listing catalysts

1/2 filings (Artemis) confirm Main Board approvals effective within 2 days (Mar 12, 2026), signaling faster SEBI/NSE timelines vs historical lags [IMPLICATION: Bullish liquidity influx]

1/2 companies (Mahamaya) reschedule 56% unutilized funds to 2028 due to FY windows/procurement, avg utilization 44% in 4 months [IMPLICATION: Monitor execution to avoid value traps]

Artemis positive (10/10 materiality) vs Mahamaya neutral, aggregate skews bullish on completions over deployments [IMPLICATION: Favor listed names]

Sequential plant projects (Mahamaya) drive extensions, no capital reallocation/dividends noted across filings [IMPLICATION: Patience for growth inflection]

Both cite SEBI LODR (Reg 32, circular resolutions), BSE intimations standard, low violation risk [IMPLICATION: Stable IPO ecosystem]

Zero insider trades, buybacks, or dividends in filings, focus purely on IPO milestones [IMPLICATION: Pure-play event driven]

Monitor trading debut and volume on NSE Main Board (AEPL) starting Mar 12, 2026 for price stabilization [Mar 12, 2026]

Track Reg 32 disclosures on ₹34.49 Cr unutilized proceeds deployment per Audit Committee/Monitoring Agency [Ongoing, next Q]

Watch BSE activation post-NSE listing for dual-market liquidity and any price arbitrage [Post Mar 12, 2026]

Sequential Technical Plant progress, potential updates on procurement FY26 end [Mar 31, 2026]

New filings since last brief (1 new: Artemis), scan for additional listings in electricals/lifesciences [Next week]

Board/ investor reaction to Mar 31, 2028 extension, sentiment shift [Immediate]

Post-listing disclosures for operational metrics/ratios absent in approval [Q1 FY27]

NSE letters like LIST/246, watch for batch listings in Mar 2026 window [Mar 2026]